E. V. Gagarina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
E. V. Gagarina has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Elena A. Mershina
Lomonosov Moscow State University
15 shared publications - Roman P. Myasnikov
Department of Clinical Cardiology and Molecular Genetics, National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russian Federation
13 shared publications - Olga V. Kulikova
National Medical Research Center for Therapy and Preventive Medicine
11 shared publications - Oksana Mikhailovna Drapkina
National Medical Research Center for Therapy and Preventive Medicine, Ministry of Health of Russia
9 shared publications - Valentin Evgenievich Sinitsyn
Lomonosov Moscow State University
8 shared publications - D. A. Nefedova
National Medical Research Center for Therapy and Preventive Medicine
7 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (6) , 4900
Profile of arrhythmias and conduction disorders in patients with familial hypertrophic cardiomyopathy: data from a multicenter registry
Aim . To analyze the profile of cardiac arrhythmias and conduction disorders in patients with familial hypertrophic cardiomyopathy (HCM) based on data from the registry of the National Medical Research Center for Therapy and Preventive Medicine and the Lomonosov Moscow State University (2021-2026). Material and methods . The analysis included 136 patients (48 men, 88 women; aged 19-78 years) — probands and relatives with a verified diagnosis or pathogenic variants in genes associated with HCM. All patients underwent additional examination, including electrocardiography (ECG) and Holter ECG monitoring. Based on this examination, 81 patients with arrhythmias and conduction disorders were identified. Genetic testing identified variants in the MYH7 , MYBPC3 , MYL2 , DSG2 , JPH2 , FLNC , ALPK3 , CACNA1C , ACTC1 , LDB3 , and TNNI3 genes in 60 patients. Results . Atrial fibrillation was recorded in 13,9% of cases (permanent in 3,7%, paroxysmal in 9,6%), ventricular premature beats in 59,6%, and ventricular fibrillation in 2,2%. Ventricular tachycardia (VT) was detected in 24,3% of all registry patients and in 34% of patients with gene variants (n=60). Degree I atrioventricular (AV) block was detected in 11% of cases, and degree II-III AV block — in 4,4%, left bundle branch block — in 5,9%. In genetic analysis, VT (80 vs 20%, p=0,001) and first degree AV block (45 vs 8%, padj=0,027) were more common in carriers of variants in the MYBPC3 gene (n=20) compared with MYH7 (n=25). The groups did not differ in interventricular septal thickness and left ventricular mass index after adjustment for sex, age and body mass index (BMI), whereas LV posterior wall thickness was higher in the MYBPC3 group (padj=0,028). The median risk of sudden cardiac death, calculated according to the Hypertrophic Cardiomyopathy. Risk-Sudden Cardiac Death (HCM Risk-SCD) score was 4,9% [3,4; 7,2] over 5 years n carriers in the MYBPC3 gene variants, compared to 3,1% [2,2; 6,8] (p=0,916) in carriers of MYH7 variants. However, no significant differences were found between the groups. Conclusion . The incidence of VT in familial HCM varies significantly depending on the genotype, reaching 80% in carriers of MYBPC3 variants. Patients with familial HCM, especially those carrying MYBPC3 variants, are recommended to undergo follow-up monitoring with Holter ECG every 6-12 months for the early detection of VT. Detection of VT allows for stratification of sudden cardiac death risk according to the HCM Risk-SCD score and determines indications for implantable cardioverter-defibrillator (ICD).
- 31 July 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (6) , 4900
Open AccessProfile of arrhythmias and conduction disorders in patients with familial hypertrophic cardiomyopathy: data from a multicenter registry
Aim . To analyze the profile of cardiac arrhythmias and conduction disorders in patients with familial hypertrophic cardiomyopathy (HCM) based on data from the registry of the National Medical Research Center for Therapy and Preventive Medicine and the Lomonosov Moscow State University (2021-2026). Material and methods . The analysis included 136 patients (48 men, 88 women; aged 19-78 years) — probands and relatives with a verified diagnosis or pathogenic variants in genes associated with HCM. All patients underwent additional examination, including electrocardiography (ECG) and Holter ECG monitoring. Based on this examination, 81 patients with arrhythmias and conduction disorders were identified. Genetic testing identified variants in the MYH7 , MYBPC3 , MYL2 , DSG2 , JPH2 , FLNC , ALPK3 , CACNA1C , ACTC1 , LDB3 , and TNNI3 genes in 60 patients. Results . Atrial fibrillation was recorded in 13,9% of cases (permanent in 3,7%, paroxysmal in 9,6%), ventricular premature beats in 59,6%, and ventricular fibrillation in 2,2%. Ventricular tachycardia (VT) was detected in 24,3% of all registry patients and in 34% of patients with gene variants (n=60). Degree I atrioventricular (AV) block was detected in 11% of cases, and degree II-III AV block — in 4,4%, left bundle branch block — in 5,9%. In genetic analysis, VT (80 vs 20%, p=0,001) and first degree AV block (45 vs 8%, padj=0,027) were more common in carriers of variants in the MYBPC3 gene (n=20) compared with MYH7 (n=25). The groups did not differ in interventricular septal thickness and left ventricular mass index after adjustment for sex, age and body mass index (BMI), whereas LV posterior wall thickness was higher in the MYBPC3 group (padj=0,028). The median risk of sudden cardiac death, calculated according to the Hypertrophic Cardiomyopathy. Risk-Sudden Cardiac Death (HCM Risk-SCD) score was 4,9% [3,4; 7,2] over 5 years n carriers in the MYBPC3 gene variants, compared to 3,1% [2,2; 6,8] (p=0,916) in carriers of MYH7 variants. However, no significant differences were found between the groups. Conclusion . The incidence of VT in familial HCM varies significantly depending on the genotype, reaching 80% in carriers of MYBPC3 variants. Patients with familial HCM, especially those carrying MYBPC3 variants, are recommended to undergo follow-up monitoring with Holter ECG every 6-12 months for the early detection of VT. Detection of VT allows for stratification of sudden cardiac death risk according to the HCM Risk-SCD score and determines indications for implantable cardioverter-defibrillator (ICD).
- Open Access
- 26 February 2026
- Published by ECO-Vector LLC (Publications) in Digital Diagnostics
- Vol. 7 (1) , 5-22
The role of myocardial strain assessment using cardiac magnetic resonance imaging in patients with non-compacted left ventricular myocardium: determination of subclinical contractility disorder
BACKGROUND: Non-compacted left ventricular myocardium is a phenotypic variant of the myocardium structure with increased trabecularity and the formation of two distinct layers: compacted and non-compacted. It is known that patients with non-compacted left ventricular myocardium gradually develop contractile dysfunction, leading to chronic heart failure. Increased trabecularity can be observed both in healthy individuals and in certain non-ischemic heart diseases, particularly in dilated cardiomyopathy. In some cases, their differential diagnosis may be complicated, especially when the left ventricle ejection fraction is not reduced or is moderately reduced, and left ventricular dilation is minimal. Recently, publications have reported that myocardial strain parameters assessed using echocardiography and/or cardiac magnetic resonance imaging can detect subclinical disorders of myocardial contractility. AIM: To assess the myocardial strain parameters using cardiac magnetic resonance imaging in patients with non-compacted left ventricular myocardium and preserved left ventricle ejection fraction compared with patients with dilated cardiomyopathy and healthy controls, and to determine the diagnostic value of these parameters for detecting subclinical disorders of myocardial contractility. METHODS: This multicenter, observational, retrospective, cross-sectional study included patients with non-compacted left ventricular myocardium with preserved left ventricle ejection fraction (group 1), healthy volunteers (group 2), and patients with dilated cardiomyopathy (group 3). All patients underwent CMR with intravenous contrast administration. RESULTS: A total of 112 participants were enrolled: 16 patients with non-compacted left ventricular myocardium with preserved left ventricle ejection fraction (group 1), 51 patients in the control group without pathological changes in heart chambers according to cardiac magnetic resonance imaging (group 2), and 45 patients with dilated cardiomyopathy (group 3). Mutations in the MYH7, MYBPC3, TTN, and DES genes had been previously detected in all patients with non-compacted left ventricular myocardium with preserved left ventricle ejection fraction. Analysis of the myocardial strain parameters revealed a decrease in the global and segmental strain parameters in patients with dilated cardiomyopathy; a decrease in longitudinal and circumferential strain in patients with non-compacted left ventricular myocardium compared with the control group in the middle and apical segments, and a decrease in radial strain in all segments. CONCLUSION: Myocardial strain assessment can serve as a valuable diagnostic tool for detecting early contractility disorders in patients with non-compacted left ventricular myocardium with preserved left ventricle ejection fraction.
- 26 February 2026
- Published by ECO-Vector LLC (Publications) in Digital Diagnostics
- Vol. 7 (1) , 5-22
Open AccessThe role of myocardial strain assessment using cardiac magnetic resonance imaging in patients with non-compacted left ventricular myocardium: determination of subclinical contractility disorder
BACKGROUND: Non-compacted left ventricular myocardium is a phenotypic variant of the myocardium structure with increased trabecularity and the formation of two distinct layers: compacted and non-compacted. It is known that patients with non-compacted left ventricular myocardium gradually develop contractile dysfunction, leading to chronic heart failure. Increased trabecularity can be observed both in healthy individuals and in certain non-ischemic heart diseases, particularly in dilated cardiomyopathy. In some cases, their differential diagnosis may be complicated, especially when the left ventricle ejection fraction is not reduced or is moderately reduced, and left ventricular dilation is minimal. Recently, publications have reported that myocardial strain parameters assessed using echocardiography and/or cardiac magnetic resonance imaging can detect subclinical disorders of myocardial contractility. AIM: To assess the myocardial strain parameters using cardiac magnetic resonance imaging in patients with non-compacted left ventricular myocardium and preserved left ventricle ejection fraction compared with patients with dilated cardiomyopathy and healthy controls, and to determine the diagnostic value of these parameters for detecting subclinical disorders of myocardial contractility. METHODS: This multicenter, observational, retrospective, cross-sectional study included patients with non-compacted left ventricular myocardium with preserved left ventricle ejection fraction (group 1), healthy volunteers (group 2), and patients with dilated cardiomyopathy (group 3). All patients underwent CMR with intravenous contrast administration. RESULTS: A total of 112 participants were enrolled: 16 patients with non-compacted left ventricular myocardium with preserved left ventricle ejection fraction (group 1), 51 patients in the control group without pathological changes in heart chambers according to cardiac magnetic resonance imaging (group 2), and 45 patients with dilated cardiomyopathy (group 3). Mutations in the MYH7, MYBPC3, TTN, and DES genes had been previously detected in all patients with non-compacted left ventricular myocardium with preserved left ventricle ejection fraction. Analysis of the myocardial strain parameters revealed a decrease in the global and segmental strain parameters in patients with dilated cardiomyopathy; a decrease in longitudinal and circumferential strain in patients with non-compacted left ventricular myocardium compared with the control group in the middle and apical segments, and a decrease in radial strain in all segments. CONCLUSION: Myocardial strain assessment can serve as a valuable diagnostic tool for detecting early contractility disorders in patients with non-compacted left ventricular myocardium with preserved left ventricle ejection fraction.
- 8 February 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (12)
Comparative characteristics of structural and functional echocardiographic parameters in patients with familial hypertrophic cardiomyopathy with MYBPC3 and MYH7 gene variants
Aim. To compare echocardiographic parameters in patients with familial hypertrophic cardiomyopathy and confirmed variants in the MYH7 and MYBPC3 genes. Material and methods. This study included a comprehensive assessment of echocardiographic parameters in 48 patients with hypertrophic cardiomyopathy, including 14 men and 34 women, aged 18-77 years. Subjects were divided into two groups based on confirmed variants in the MYH7 and MYBPC3 genes. Results. Patients with a MYBPC3 gene variant had significantly larger right atrial size and left ventricular (LV) posterior wall thickness (p=0,42, p=0,002), while LV systolic function, assessed using the additional speckle tracking echocardiography, was significantly lower compared to patients with a variant in the MYH7 gene (p=0,021). Conclusion. Patients with a variant in the MYBPC3 gene showed significant changes in structural and functional echocardiography parameters, indicating a less favorable prognosis for this group of patients.
- 8 February 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (12)
Comparative characteristics of structural and functional echocardiographic parameters in patients with familial hypertrophic cardiomyopathy with MYBPC3 and MYH7 gene variants
Aim. To compare echocardiographic parameters in patients with familial hypertrophic cardiomyopathy and confirmed variants in the MYH7 and MYBPC3 genes. Material and methods. This study included a comprehensive assessment of echocardiographic parameters in 48 patients with hypertrophic cardiomyopathy, including 14 men and 34 women, aged 18-77 years. Subjects were divided into two groups based on confirmed variants in the MYH7 and MYBPC3 genes. Results. Patients with a MYBPC3 gene variant had significantly larger right atrial size and left ventricular (LV) posterior wall thickness (p=0,42, p=0,002), while LV systolic function, assessed using the additional speckle tracking echocardiography, was significantly lower compared to patients with a variant in the MYH7 gene (p=0,021). Conclusion. Patients with a variant in the MYBPC3 gene showed significant changes in structural and functional echocardiography parameters, indicating a less favorable prognosis for this group of patients.
- 8 February 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (12)
Comparative characteristics of structural and functional echocardiographic parameters in patients with familial hypertrophic cardiomyopathy with MYBPC3 and MYH7 gene variants
Aim. To compare echocardiographic parameters in patients with familial hypertrophic cardiomyopathy and confirmed variants in the MYH7 and MYBPC3 genes. Material and methods. This study included a comprehensive assessment of echocardiographic parameters in 48 patients with hypertrophic cardiomyopathy, including 14 men and 34 women, aged 18-77 years. Subjects were divided into two groups based on confirmed variants in the MYH7 and MYBPC3 genes. Results. Patients with a MYBPC3 gene variant had significantly larger right atrial size and left ventricular (LV) posterior wall thickness (p=0,42, p=0,002), while LV systolic function, assessed using the additional speckle tracking echocardiography, was significantly lower compared to patients with a variant in the MYH7 gene (p=0,021). Conclusion. Patients with a variant in the MYBPC3 gene showed significant changes in structural and functional echocardiography parameters, indicating a less favorable prognosis for this group of patients.
- 8 February 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (12)
Comparative characteristics of structural and functional echocardiographic parameters in patients with familial hypertrophic cardiomyopathy with MYBPC3 and MYH7 gene variants
Aim. To compare echocardiographic parameters in patients with familial hypertrophic cardiomyopathy and confirmed variants in the MYH7 and MYBPC3 genes. Material and methods. This study included a comprehensive assessment of echocardiographic parameters in 48 patients with hypertrophic cardiomyopathy, including 14 men and 34 women, aged 18-77 years. Subjects were divided into two groups based on confirmed variants in the MYH7 and MYBPC3 genes. Results. Patients with a MYBPC3 gene variant had significantly larger right atrial size and left ventricular (LV) posterior wall thickness (p=0,42, p=0,002), while LV systolic function, assessed using the additional speckle tracking echocardiography, was significantly lower compared to patients with a variant in the MYH7 gene (p=0,021). Conclusion. Patients with a variant in the MYBPC3 gene showed significant changes in structural and functional echocardiography parameters, indicating a less favorable prognosis for this group of patients.
- Open Access
- 8 February 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (12) , 4677
Сomparative analysis of cardiac magnetic resonance imaging data in patients with hypertrophic cardiomyopathy and Anderson-Fabry disease
Aim. Cardiac involvement in Anderson-Fabry disease (AFD) is often characterized by left ventricular hypertrophy (LVH), which can be mistaken for hypertrophic cardiomyopathy (HCM). The aim was to analyze and compare morphological and functional cardiac changes using multiparametric magnetic resonance imaging (MRI) in patients with AFD, HCM, and healthy volunteers. Material and methods. The study included 131 patients with HCM, 42 patients with AFD, and 18 healthy volunteers. Multiparametric cardiac MRI was performed using a 3T scanner. Results. LVH was detected in 55% of patients with AFD. Signs of myocardial fibrosis were more common in HCM than in AFD+LVH (86% vs 35%, pConclusion. Native T1 mapping values in AFD, regardless of LVH, are lower than those in patients with HCM and healthy volunteers and can be used in the early diagnosis of myocardial involvement in AFD.
- 8 February 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (12) , 4677
Open AccessСomparative analysis of cardiac magnetic resonance imaging data in patients with hypertrophic cardiomyopathy and Anderson-Fabry disease
Aim. Cardiac involvement in Anderson-Fabry disease (AFD) is often characterized by left ventricular hypertrophy (LVH), which can be mistaken for hypertrophic cardiomyopathy (HCM). The aim was to analyze and compare morphological and functional cardiac changes using multiparametric magnetic resonance imaging (MRI) in patients with AFD, HCM, and healthy volunteers. Material and methods. The study included 131 patients with HCM, 42 patients with AFD, and 18 healthy volunteers. Multiparametric cardiac MRI was performed using a 3T scanner. Results. LVH was detected in 55% of patients with AFD. Signs of myocardial fibrosis were more common in HCM than in AFD+LVH (86% vs 35%, pConclusion. Native T1 mapping values in AFD, regardless of LVH, are lower than those in patients with HCM and healthy volunteers and can be used in the early diagnosis of myocardial involvement in AFD.
- Open Access
- 22 January 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (6) , 578-584
Conduction disorders as an early marker of cardiac glycogenosis (PRKAG2 syndrome)
The article presents a clinical case of familial PRKAG2 -cardiomyopathy, illustrating diagnostic challenges and the importance of molecular genetic verification. A comprehensive clinical and instrumental examination of the proband and close relatives was performed, along with whole-exome sequencing. The proband, with a family history of sudden cardiac death, was found to have apical hypertrophy of the left ventricle, a history of supraventricular extrasystole, and atrial fibrillation. Her younger son was documented to have ventricular pre-excitation syndrome, bradycardia, and syncopal episodes. Genetic analysis identified a heterozygous pathogenic variant c.905G>A (p.Arg302Gln; rs121908987) in the PRKAG2 gene in both the proband and her younger son. The described case emphasizes that cardiomyopathy associated with the p.Arg302Gln variant can present with moderate myocardial hypertrophy, while electrophysiological disturbances (pre-excitation, bradyarrhythmias) and a burdened family history of sudden death take precedence in the clinical picture. Thus, the combination of conduction disorders (especially WPW syndrome) with mild hypertrophy and familial cases of sudden death forms a characteristic «red flag» for this disease. The presence of such a combination of signs in the family history necessitates targeted genetic testing for diagnosis verification and correct risk stratification.
- 22 January 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (6) , 578-584
Open AccessConduction disorders as an early marker of cardiac glycogenosis (PRKAG2 syndrome)
The article presents a clinical case of familial PRKAG2 -cardiomyopathy, illustrating diagnostic challenges and the importance of molecular genetic verification. A comprehensive clinical and instrumental examination of the proband and close relatives was performed, along with whole-exome sequencing. The proband, with a family history of sudden cardiac death, was found to have apical hypertrophy of the left ventricle, a history of supraventricular extrasystole, and atrial fibrillation. Her younger son was documented to have ventricular pre-excitation syndrome, bradycardia, and syncopal episodes. Genetic analysis identified a heterozygous pathogenic variant c.905G>A (p.Arg302Gln; rs121908987) in the PRKAG2 gene in both the proband and her younger son. The described case emphasizes that cardiomyopathy associated with the p.Arg302Gln variant can present with moderate myocardial hypertrophy, while electrophysiological disturbances (pre-excitation, bradyarrhythmias) and a burdened family history of sudden death take precedence in the clinical picture. Thus, the combination of conduction disorders (especially WPW syndrome) with mild hypertrophy and familial cases of sudden death forms a characteristic «red flag» for this disease. The presence of such a combination of signs in the family history necessitates targeted genetic testing for diagnosis verification and correct risk stratification.
- Open Access
- 14 January 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (5) , 475-483
Family clinical case report of a MYBPC3 gene sequence variant with diverse phenotypic expressions
In recent years, the results of numerous scientific studies have shifted the focus from phenotypic traits to genotype as the basis for the modern classification of primary cardiomyopathies (CMP). An example of this genotype-specific approach is CMP associated with variants in the MYBPC3 gene, which holds significant clinical relevance. One feature of this heart disease is significant phenotypic heterogeneity. Furthermore, there is high variability in the disease penetrance and expressivity, even among patients with the same MYBPC3 gene variant, which complicates risk stratification, prognosis determination and the personalization of therapeutic approach. This article presents a case of a family with a likely pathogenic MYBPC3 gene variant (rs727503195, c.1790G>A, p.Arg597Gln) in three generations. The described family case clearly demonstrates the significant heterogeneity in the CMP clinical and morphological characteristics associated with MYBPC3 gene variants.
- 14 January 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (5) , 475-483
Open AccessFamily clinical case report of a MYBPC3 gene sequence variant with diverse phenotypic expressions
In recent years, the results of numerous scientific studies have shifted the focus from phenotypic traits to genotype as the basis for the modern classification of primary cardiomyopathies (CMP). An example of this genotype-specific approach is CMP associated with variants in the MYBPC3 gene, which holds significant clinical relevance. One feature of this heart disease is significant phenotypic heterogeneity. Furthermore, there is high variability in the disease penetrance and expressivity, even among patients with the same MYBPC3 gene variant, which complicates risk stratification, prognosis determination and the personalization of therapeutic approach. This article presents a case of a family with a likely pathogenic MYBPC3 gene variant (rs727503195, c.1790G>A, p.Arg597Gln) in three generations. The described family case clearly demonstrates the significant heterogeneity in the CMP clinical and morphological characteristics associated with MYBPC3 gene variants.
- Open Access
- 6 May 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (6S) , 6298
Modern features of coronary thrombosis imaging in non-ST-elevation acute coronary syndrome
Cardiovascular diseases, in particular ST-elevation (STE-ACS) and non-ST-elevation (NSTE-ACS) acute coronary syndrome remain one of the main causes of death worldwide. Published data indicate that in a number of patients, the cause of NSTE-ACS is infarct-related artery occlusion. In modern medicine, there are both invasive and non-invasive coronary thrombosis imaging methods. The aim of the study was to analyze and systematize the literature data on coronary thrombosis imaging methods. The review was prepared using publications indexed in the PubMed, Google Scholar, Web of Science, and Cyberleninka databases. The search depth was 5 years, starting from 2020. The review is based on summarized data from the most relevant clinical studies, reports, and systematic reviews. The conducted literature analysis showed that both invasive and non-invasive imaging methods have a number of advantages and disadvantages. In this regard, improving these techniques remains an urgent research task.
- 6 May 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (6S) , 6298
Open AccessModern features of coronary thrombosis imaging in non-ST-elevation acute coronary syndrome
Cardiovascular diseases, in particular ST-elevation (STE-ACS) and non-ST-elevation (NSTE-ACS) acute coronary syndrome remain one of the main causes of death worldwide. Published data indicate that in a number of patients, the cause of NSTE-ACS is infarct-related artery occlusion. In modern medicine, there are both invasive and non-invasive coronary thrombosis imaging methods. The aim of the study was to analyze and systematize the literature data on coronary thrombosis imaging methods. The review was prepared using publications indexed in the PubMed, Google Scholar, Web of Science, and Cyberleninka databases. The search depth was 5 years, starting from 2020. The review is based on summarized data from the most relevant clinical studies, reports, and systematic reviews. The conducted literature analysis showed that both invasive and non-invasive imaging methods have a number of advantages and disadvantages. In this regard, improving these techniques remains an urgent research task.
- Open Access
- 8 October 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (11) , 6113
Comparison of cardiac morphological and functional changes according to magnetic resonance imaging with the genetic testing data in patients with hypertrophic cardiomyopathy
Aim. To analyze the data of cardiac magnetic resonance imaging (MRI) of patients with hypertrophic cardiomyopathy (HCM) depending on the results of genetic testing.Material and methods. The study included 83 patients with a diagnosis of HCM (39 men, 44 women, mean age 50,4±14,9 years) who had no contraindications to MRI. Cardiac MRI was performed on 1,5 T and 3 T MRI systems using a standard protocol. T1 and T2 mapping was performed in 41 patients, and the extracellular volume fraction was estimated. All patients underwent genetic testing with assessment of sarcomeric genes, two non-sarcomeric genes associated with HCM, and genes of syndromic diseases (HCM phenocopies).Results. Positive results of genetic testing were obtained in 49 (59%) of 83 patients: MYBPC3 29%, MYH7 17%, TPM1 5%, FLNC 4%, MYL2 2%, TNNC1 1%, TNNI3 1% (genotype-positive group (G+)). Negative results of genetic testing were obtained in 34 (41%) patients (genotype-negative group (G-)). In the G-group, patients were significantly older than in G+ (57,7±12,9 vs 45,3±14,2 years, pConclusion. In patients with HCM, a positive genetic analysis, regardless of the affected gene, is associated with a greater severity of fibrosis according to MRI data, which indicates a less favorable prognosis.
- 8 October 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (11) , 6113
Open AccessComparison of cardiac morphological and functional changes according to magnetic resonance imaging with the genetic testing data in patients with hypertrophic cardiomyopathy
Aim. To analyze the data of cardiac magnetic resonance imaging (MRI) of patients with hypertrophic cardiomyopathy (HCM) depending on the results of genetic testing.Material and methods. The study included 83 patients with a diagnosis of HCM (39 men, 44 women, mean age 50,4±14,9 years) who had no contraindications to MRI. Cardiac MRI was performed on 1,5 T and 3 T MRI systems using a standard protocol. T1 and T2 mapping was performed in 41 patients, and the extracellular volume fraction was estimated. All patients underwent genetic testing with assessment of sarcomeric genes, two non-sarcomeric genes associated with HCM, and genes of syndromic diseases (HCM phenocopies).Results. Positive results of genetic testing were obtained in 49 (59%) of 83 patients: MYBPC3 29%, MYH7 17%, TPM1 5%, FLNC 4%, MYL2 2%, TNNC1 1%, TNNI3 1% (genotype-positive group (G+)). Negative results of genetic testing were obtained in 34 (41%) patients (genotype-negative group (G-)). In the G-group, patients were significantly older than in G+ (57,7±12,9 vs 45,3±14,2 years, pConclusion. In patients with HCM, a positive genetic analysis, regardless of the affected gene, is associated with a greater severity of fibrosis according to MRI data, which indicates a less favorable prognosis.
- Open Access
- 30 September 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (10S) , 6142
Danon disease in women: a modern view of the problem: a case series
Introduction. Danon disease is a rare cardiomyopathy (CMP) with multisystem involvement, which is associated with lysosome-associated membrane protein 2 (LAMP2) gene polymorphisms. This protein is the most important regulator of autophagy and is produced mainly in the myocardium, skeletal muscles and brain. This is reflected in the classic disease triad: hypertrophic CMP, skeletal myopathy and cognitive impairment. Danon disease is characterized by maximum penetrance regardless of sex. Expressivity is much less predictable in women, given the X-linked dominant inheritance and mosaicism of cellular production of the LAMP2 protein as a result of random inactivation of one of the X chromosomes.Brief description. The article presents two clinical cases demonstrating different disease courses in women with Danon disease. The analysis of case records, clinical performance, paraclinical data were carried out.Discussion. In recent years, the widespread development of molecular genetic diagnostics and imaging methods has led to the accumulation of data on natural course and prognosis of Danon disease. It became clear that in female patients with Danon disease, previously considered mainly as mutation carriers, clinical manifestations can vary from low-symptom phenotypes with isolated CMP to severe multisystemic involvement and early onset. Raising awareness among practitioners about the Danon disease specifics in women, multidisciplinary examination, and genetic testing are the basis for timely diagnosis, risk stratification, and treatment initiation.
- 30 September 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (10S) , 6142
Open AccessDanon disease in women: a modern view of the problem: a case series
Introduction. Danon disease is a rare cardiomyopathy (CMP) with multisystem involvement, which is associated with lysosome-associated membrane protein 2 (LAMP2) gene polymorphisms. This protein is the most important regulator of autophagy and is produced mainly in the myocardium, skeletal muscles and brain. This is reflected in the classic disease triad: hypertrophic CMP, skeletal myopathy and cognitive impairment. Danon disease is characterized by maximum penetrance regardless of sex. Expressivity is much less predictable in women, given the X-linked dominant inheritance and mosaicism of cellular production of the LAMP2 protein as a result of random inactivation of one of the X chromosomes.Brief description. The article presents two clinical cases demonstrating different disease courses in women with Danon disease. The analysis of case records, clinical performance, paraclinical data were carried out.Discussion. In recent years, the widespread development of molecular genetic diagnostics and imaging methods has led to the accumulation of data on natural course and prognosis of Danon disease. It became clear that in female patients with Danon disease, previously considered mainly as mutation carriers, clinical manifestations can vary from low-symptom phenotypes with isolated CMP to severe multisystemic involvement and early onset. Raising awareness among practitioners about the Danon disease specifics in women, multidisciplinary examination, and genetic testing are the basis for timely diagnosis, risk stratification, and treatment initiation.